A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

NCT05001282 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

79

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of Funding - no safety issue with Drug; Company Permanently Closed

Conditions

Ovarian Cancer
Ovarian Neoplasms
Ovarian Carcinoma
Endometrial Cancer
Ovary Cancer
Ovary Neoplasm
Ovary Disease
Ovary Metastasis
Ovarian Diseases
Ovarian Cancer Stage
Ovarian Epithelial Cancer
Ovarian Adenocarcinoma
Ovarian Serous Adenocarcinoma
Ovarian Neoplasm Epithelial
Ovarian Cancer Recurrent
Endometrial Diseases
Endometrial Adenocarcinoma
Endometrial Carcinosarcoma
Endometrial Clear Cell Adenocarcinoma
Endometrioid Adenocarcinoma
Endometrial Neoplasms
Endometrial Cancer Recurrent
Endometrioid Tumor
Fallopian Tube Cancer
Peritoneal Cancer

Interventions

DRUG: ELU001

Sponsor

Elucida Oncology